CD8A and neoplasm: To evaluate the contribution of different cell types to antitumor activity and toxicity, CTRL-not-α-mIL2 therapy was administered to tumor-bearing mice that were depleted of either CD4+ cells (via anti-CD4), CD8+ cells (via anti-CD8β), or NK cells (via anti-NK1.1).